Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This is a phase II, non-randomised, multicentre study to assess the safety and efficacy of
the PD-L1 inhibitor, avelumab, in a previously untreated fit population of high risk stage
II, stage III and stage IV classical Hodgkin lymphoma.